TNFSF10 and neoplasm: Although we found no specific correlation between TRAIL-receptors expression and tumor stage in our cohort, the fact that TRAIL-receptors expression was not associated with any pathological parameter supports the hypothesis that, rather than influencing tumor initiation, loss of TRAIL-receptors might affect tumor progression at a later stage due to the selection of cell clones resistant to circulating TRAIL and to immune-mediated mechanisms controlling clearance of metastatic cells [32], [33].